ADG126 for Cancer
Phase-Based Progress Estimates
Effectiveness
Safety
HonorHealth Research Institute, Scottsdale, AZ
Cancer+1 More
ADG126 - DrugEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of an ADG126-pembrolizumab combination regimen in patients with advanced/metastatic solid tumors.
Eligible Conditions
- Cancer
- Advanced/Metastatic Solid Tumors
Treatment Effectiveness
Effectiveness Progress
Study Objectives
4 Primary · 8 Secondary · Reporting Duration: 9 months
9 months
Dose-limiting toxicity (DLT) and RP2D for ADG126 in combination with pembrolizumab.
recommended Phase 2 dose (RP2D) of ADG126 in combination with pembrolizumab
the maximum tolerated dose (MTD) for ADG126 in combination with pembrolizumab.
the safety and tolerability of ADG126 in combination with pembrolizumab
Year 2
Incidence of ADAs
Maximum (peak) plasma concentration (Cmax)
Pharmacokinetic (PK) profile/parameters
Time to maximum (peak) concentration (Tmax)
To assess the disease control rate (DCR)
To assess the overall survival (OS)
To assess the progression free survival (PFS)
Trough concentration (Ctrough)
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
ADG126 in combination with Pembrolizumab
1 of 1
Experimental Treatment
102 Total Participants · 1 Treatment Group
Primary Treatment: ADG126 · No Placebo Group · Phase 1
ADG126 in combination with Pembrolizumab
Drug
Experimental Group · 1 Intervention: ADG126 · Intervention Types: DrugTrial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 9 months
Closest Location: HonorHealth Research Institute · Scottsdale, AZ
2017First Recorded Clinical Trial
0 TrialsResearching Cancer
32 CompletedClinical Trials
Who is running the clinical trial?
Merck Sharp & Dohme LLCIndustry Sponsor
3,626 Previous Clinical Trials
4,948,326 Total Patients Enrolled
Adagene IncLead Sponsor
8 Previous Clinical Trials
582 Total Patients Enrolled
Jiping zha, MDStudy ChairAdagene Inc
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:Patients with serum bilirubin increases due to documented underlying Gilbert's Syndrome or familial benign unconjugated hyperbilirubinemia may be enrolled.
You have advanced or metastatic solid tumors, histologically or pathologically confirmed, who have progressed after all standard therapies, or for whom no further standard therapy exists.
Patients should have at least 1 measurable lesion at baseline according to the definition of RECIST v1.1
ANC ≥ 1.5 ×109/L, without the use of granulocyte colony stimulating factor such as filgrastim within 2 weeks prior to study treatment.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments